BioNexus Gene Lab

Historical price data

BioNexus Gene Lab is a public molecular diagnostics company focused on predictive health through early risk assessment. Its core technology, based on decades of research by its late co-founder, analyzes dynamic RNA signatures in blood to screen for predispositions to major diseases. The company's strategy is to commercialize its BGS test as a service from its Malaysian operational hub, targeting the growing global market for liquid biopsy and preventive personalized medicine.

Blood-based Genomic Screening (BGS) platform analyzing dynamic RNA expression profiles in blood to assess current risk for diseases including cancer, inflammatory conditions, and osteoarthritis.

Faces competition from large liquid biopsy companies (e.g., GRAIL, Freenome), global diagnostics giants (Roche, Abbott), and direct-to-consumer genetic test providers. Its small size and regional focus are significant competitive disadvantages against deep-pocketed players conducting large-scale trials.